Market Place
Sourcing Support
RedHill to Present Opaganib at U.S. Government Conference
28 Oct 2024 //
PR NEWSWIRE
RedHill Collaborates To Develop Opaganib Against Phosgene Injury
22 Oct 2024 //
PR NEWSWIRE
RedHill Biopharma Secures BARDA Funding For Opaganib
14 Oct 2024 //
PR NEWSWIRE
RedHill and Medi-Cal Maintain Talicia® Reimbursement for 15M Californians
01 Oct 2024 //
PR NEWSWIRE
RedHill Announces New U.S. Patent For Opaganib, Valid Until 2041
30 Sep 2024 //
PR NEWSWIRE
RedHill`s Talicia Listed As First-Line For H. Pylori In ACG Guidelines
09 Sep 2024 //
PR NEWSWIRE
RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
05 Sep 2024 //
PR NEWSWIRE
Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality
03 Sep 2024 //
PR NEWSWIRE
RedHill Biopharma Announces First Half 2024 Business Highlights
29 Aug 2024 //
PR NEWSWIRE
RedHill`s Opaganib Gets FDA Orphan Drug Status For Childhood Neuroblastoma
26 Aug 2024 //
PR NEWSWIRE
Talicia® Launched in the United Arab Emirates
21 Aug 2024 //
PR NEWSWIRE
RedHill Announces Positive Obesity and Diabetes Results with Opaganib
19 Aug 2024 //
PR NEWSWIRE
RedHill Biopharma Announces Plan to Implement ADS Ratio Change
16 Aug 2024 //
PR NEWSWIRE
RedHill`s RHB-104 Shows 64% Increased Efficacy In Crohn`s Disease
01 Aug 2024 //
PR NEWSWIRE
RedHill Biopharma Settles Obligations And Removes Talicia Lien
22 Jul 2024 //
PR NEWSWIRE
RedHill Biopharma Terminates License Agreement for Aemcolo®
09 Jul 2024 //
PR NEWSWIRE
RedHill Patents Opaganib Combo With Checkpoint Inhibitors Through 2040
03 Jun 2024 //
PR NEWSWIRE
RedHill obtains Chinese patent for Opaganib against Ebola
06 May 2024 //
PR NEWSWIRE
RedHill Enrolls First COVID-19 Govt-Supported Study Patient
24 Apr 2024 //
PR NEWSWIRE
RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights
08 Apr 2024 //
PR NEWSWIRE
RedHill Biopharma Announces $1.25 Million Registered Direct Offering
02 Apr 2024 //
PR NEWSWIRE
RedHill Announces New USPTO Patent Covering Talicia® Through 2034
11 Mar 2024 //
PR NEWSWIRE
RedHill`s Opaganib Selected for Evaluation by BARDA
05 Mar 2024 //
PR NEWSWIRE
RedHill`s Opaganib Protects Against Radiation-Induced Lung Inflammation
20 Feb 2024 //
PR NEWSWIRE
RedHill Biopharma Announces Closing of $8 Million Registered Direct Offering
26 Jan 2024 //
PR NEWSWIRE
RedHill Announces New USPTO Patent Grant for Talicia
25 Jan 2024 //
PR NEWSWIRE
RedHill Biopharma Announces $8 Million Registered Direct Offering
25 Jan 2024 //
PR NEWSWIRE
RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
12 Dec 2023 //
PR NEWSWIRE
RedHill Announces Non-Dilutive Funding of Entire RHB-107 Phase 2 Study
04 Dec 2023 //
PR NEWSWIRE
RedHill Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia
27 Nov 2023 //
PR NEWSWIRE
RedHill Announces the Transfer of its Listing to The Nasdaq Capital Market
14 Nov 2023 //
PR NEWSWIRE
RedHill and U.S. Army Announce Opaganib`s Ebola Virus Disease Survival Benefit
03 Oct 2023 //
PR NEWSWIRE
An antiviral once tested for COVID works in mice with Ebola
03 Oct 2023 //
FIERCE BIOTECH
RedHill Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price
22 Sep 2023 //
PR NEWSWIRE
RedHill Announces FDA sNDA Approval for Talicia®
18 Sep 2023 //
PR NEWSWIRE
RedHill Announces New USPTO Notice of Patent Allowance for Opaganib
05 Sep 2023 //
PR NEWSWIRE
RedHill Biopharma Provides H1/23 Financial Results and Operational Highlights
17 Aug 2023 //
PR NEWSWIRE
RedHill Biopharma Announces Talicia Approved in the United Arab Emirates
01 Aug 2023 //
PR NEWSWIRE
RedHill`s RHB-107 Included in U.S. Government-Supported COVID-19 Platform Trial
31 Jul 2023 //
PR NEWSWIRE
RedHill Biopharma Announces Closing of $3.8 Million Registered Direct Offering
25 Jul 2023 //
PR NEWSWIRE
RedHill Announces Direct Offering and Warrant Exercise for $3.8M Gross Proceeds
21 Jul 2023 //
PR NEWSWIRE
Phil and RedHill Biopharma Partner to Increase Access to Talicia®
06 Jul 2023 //
BUSINESSWIRE
RedHill Biopharma Announces Q1/2023 Financial Results and Operational Highlights
12 Jun 2023 //
PR NEWSWIRE
RedHill lightens load, abandoning phase 3 lung disease program
22 May 2023 //
FIERCE BIOTECH
RedHill Provides R&D Update
22 May 2023 //
PR NEWSWIRE
RedHill Biopharma Receives NASDAQ Notification Regarding Minimum Market Value
15 May 2023 //
PR NEWSWIRE
RedHill Publishes New Talicia® Data on Generic Non-Bioequivalence in AP&T
09 May 2023 //
PR NEWSWIRE
RedHill`s RHB-102 (BEKINDA®) & Opaganib Granted New Patents in Oncology Setting
01 May 2023 //
PR NEWSWIRE
RedHill Announces Q4/22 & Full-Year 2022 Results and Operational Highlights
28 Apr 2023 //
PR NEWSWIRE
RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
11 Apr 2023 //
PR NEWSWIRE
RedHill Biopharma Announces Closing of $6 Million Registered Direct Offering
03 Apr 2023 //
PR NEWSWIRE
RedHill Biopharma Announces $6 Million Registered Direct Offering
30 Mar 2023 //
PR NEWSWIRE
RedHill Initiates First Warranty Program to Refund Talicia Non-Responders
21 Mar 2023 //
PR NEWSWIRE
RedHill Biopharma Announces Plan to Implement ADS Ratio Change
16 Mar 2023 //
PR NEWSWIRE
RedHill Announces Agreement for Up To $6 Million Private Placement
08 Mar 2023 //
PR NEWSWIRE
RedHill`s Opaganib Selected by the NIH Radiation and Countermeasures Program
28 Feb 2023 //
PR NEWSWIRE
RedHill Biopharma Announces RedHill`s RHB-102 Positive MHRA Meeting & MAA Plan
16 Feb 2023 //
ACCESSWIRE
RedHill Announces Positive MHRA Meeting and Planned UK MAA of RHB-102
16 Feb 2023 //
PR NEWSWIRE
RedHill and HealthCare Agree to Extinguish All RedHill`s Debt Obligations
06 Feb 2023 //
PR NEWSWIRE
